Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia

Affiliations

¹ Hematology, P.O. S. Luca, ASL Salerno, Vallo della Lucania, Italy.
² Immunohematology Unit, AORN Giuseppe Moscati, Avellino, Italy.
³ Flow Cytometry Unit, Clinical Laboratory, Sant'Andrea Hospital, Roma, Italy.
⁴ Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
⁵ Laboratory of Clinical and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
⁶ Hematology Unit and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
⁷ Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
⁸ Hematology Unit IRCCS Fondazione Policlinico Gemelli, Catholic University of "Sacred Heart", Roma, Italy.
⁹ Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy.
¹⁰ Department of Emergency and Organ Transplantation, Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.

Giovanni D'Arena et al. Int J Lab Hematol. 2022 Jun.

. 2022 Jun;44(3):e120-e122.

doi: 10.1111/ijlh.13766. Epub 2021 Nov 18.

¹ Hematology, P.O. S. Luca, ASL Salerno, Vallo della Lucania, Italy.
² Immunohematology Unit, AORN Giuseppe Moscati, Avellino, Italy.
³ Flow Cytometry Unit, Clinical Laboratory, Sant'Andrea Hospital, Roma, Italy.
⁴ Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
⁵ Laboratory of Clinical and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
⁶ Hematology Unit and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
⁷ Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
⁸ Hematology Unit IRCCS Fondazione Policlinico Gemelli, Catholic University of "Sacred Heart", Roma, Italy.
⁹ Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy.
¹⁰ Department of Emergency and Organ Transplantation, Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.

No abstract available

Keywords: chronic lymphocytic leukemia; flow cytometry; minimal residual disease; prognosis; standardization.

References

1. Furstenau M, De Silva N, Eichhorst B, et al. Minimal residual disease assessment in CLL: ready for use in clinical routine? HemaSphere. 2019;3(5):e287.
1. Del Giudice I, Raponi S, Della Starza I, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019;9:689. doi:10.3389/fonc.2019.00689
1. European Medicines Agency. Guidelines on the Use of Minimal Residual Disease as an Endpoint in Chronic Lymphocytic Leukemia Studies. European Medicines Agency; 2014. Available online at: http://www.ema.europa.eu/documents/scientific-guideline/guideline-use-mi...
1. Thompson M, Brandler D, Nabhan C, et al. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents. JAMA Oncol. 2018;4:394-400. doi:10.1001/jamaoncol.2017.2009
1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, an supportive management of CLL. Blood. 2018;131:2745-2760.